Obesity as a risk factor for developing postoperative atrial fibrillation [5]

Chest

Volumn 129, Issue 3, 2006, Pages 828-

  Arias, Miguel A ^a,c   Sánchez Gila, Joaquín ^b  

^a Servicio Andaluz de Salud   (Spain)

^b HOSPITAL UNIVERSITARIO VIRGEN DE LAS NIEVES   (Spain)

^c NONE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

BODY MASS; BODY WEIGHT; DIASTOLE; HEART ATRIUM ENLARGEMENT; HEART ATRIUM FIBRILLATION; HEART LEFT VENTRICLE FAILURE; HUMAN; INCIDENCE; LETTER; OBESITY; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; RISK FACTOR; SURGICAL RISK; PREVALENCE; BLOOD; NOTE;

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ATRIAL FIBRILLATION; BODY MASS INDEX; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; OBESITY; POSTOPERATIVE COMPLICATIONS; RISK FACTORS;

EID: 33645117318     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.129.3.828     Document Type: Letter

References (12)

1. Amar D, Zhang H, Heerdt PM, et al. Statin use is associated with a reduction in atrial fibrillation after noncardiac thoracic surgery independent of C-reactive protein. Chest 2005; 128:3421-3427
2. Das UN. Obesity, metabolic syndrome X, and inflammation. Nutrition 2002; 18:430-432
3. Visser M, Bouter LM, McQuillan GM, et al. Elevated C-reactive protein levels in overweight and obese adults. JAMA 1999; 282:2131-2135
4. Zacharias A, Schwann TA, Riordan CJ, et al. Obesity and risk of new-onset atrial fibrillation after cardiac surgery. Circulation 2005; 112:3247-3255
5. Pritchett AM, Jacobsen SJ, Mahoney DW, et al. Left atrial volume as an index of left atrial size: a population-based study. J Am Coll Cardiol 2003; 41:1036-1043
6. Engeli S, Sharma AM. The renin-angiotensin system and natriuretic peptides in obesity-associated hypertension. J Mol Med 2001; 79:21-29
7. Iacobellis G, Ribaudo MC, Leto G, et al. Influence of excess fat on cardiac morphology and function: study in uncomplicated obesity. Obes Res 2002; 10:767-773
8. Aurigemma GP, Gaasch WH. Clinical practice: diastolic heart failure. N Engl J Med 2004; 351:1097-1105
9. Fukuta H, Sane DC, Brucks S, et al. Statin therapy may be associated with lower mortality in patients with diastolic heart failure: a preliminary report. Circulation 2005; 112:357-363
10. Takemoto M, Node K, Nakagami H, et al. Statins as antioxidant therapy for preventing cardiac myocyte hypertrophy. J Clin Invest 2001; 108:1429-1437
11. O'Driscoll G, Green D, Taylor RR. Simvastatin, an HMG-coenzyme A reductase inhibitor, improves endothelial function within 1 month. Circulation 1997; 95:1126-1131
12. Plenge JK, Hernandez TL, Weil KM, et al. Simvastatin lowers C-reactive protein within 14 days: an effect independent of low-density lipoprotein cholesterol reduction. Circulation 2002; 106:1447-1452